Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Tanja D de Gruijl"'
Autor:
Ronald J.C.L.M. Vuylsteke, Arnold Baars, Alfons J.M. van den Eertwegh, Rik J. Scheper, Tanja D. de Gruijl, Berbel J.R. Sluijter, Mari F.C.M. van den Hout, Bas D. Koster, Paul A. M. van Leeuwen, M. Petrousjka van den Tol, Barbara G. Molenkamp
Publikováno v:
Clinical Cancer Research, 23(19), 5679-5686. American Association for Cancer Research Inc.
Koster, B D, Van Den Hout, M F C M, Sluijter, B J R, Molenkamp, B G, Vuylsteke, R J C L M, Baars, A, Van Leeuwen, P A M, Scheper, R J, Petrousjka van den Tol, M, Van Den Eertwegh, A J M & De Gruijl, T D 2017, ' Local adjuvant treatment with low-dose CpG-B offers durable protection against disease recurrence in clinical stage I–II melanoma : Data from two randomized phase II trials ', Clinical Cancer Research, vol. 23, no. 19, pp. 5679-5686 . https://doi.org/10.1158/1078-0432.CCR-17-0944
Koster, B D, Van Den Hout, M F C M, Sluijter, B J R, Molenkamp, B G, Vuylsteke, R J C L M, Baars, A, Van Leeuwen, P A M, Scheper, R J, Petrousjka van den Tol, M, Van Den Eertwegh, A J M & De Gruijl, T D 2017, ' Local adjuvant treatment with low-dose CpG-B offers durable protection against disease recurrence in clinical stage I–II melanoma : Data from two randomized phase II trials ', Clinical Cancer Research, vol. 23, no. 19, pp. 5679-5686 . https://doi.org/10.1158/1078-0432.CCR-17-0944
Purpose: Although risk of recurrence after surgical removal of clinical stage I–II melanoma is considerable, there is no adjuvant therapy with proven efficacy. Here, we provide clinical evidence that a local conditioning regimen, aimed at immunolog